WCM
LXRX icon

Weld Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Weld Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,549
Closed -$150K – 786
2018
Q4 		$150K Buy
+22,549
New +$183K 0.03% 608

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Weld Capital Management's LXRX Position: Q1 2019 in Review

Weld Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2019, closing a stake of 22,549 shares — an estimated $150K sold.

Weld Capital Management first reported a position in LXRX in Q4 2018 and held it in 1 quarter. The position peaked at $150K in Q4 2018. 121 funds tracked by Wall St. Rank hold LXRX as of Q1 2019.

  • Weld Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Weld Capital Management sold 22,549 Lexicon Pharmaceuticals shares in Q1 2019, an estimated $150K.
  • Weld Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Weld Capital Management's Lexicon Pharmaceuticals position peaked at $150K in Q4 2018.
  • 121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2019.

Based on Weld Capital Management's 13F filing for Q1 2019, filed 15 May 2019.